Prelude Capital Management’s West Pharmaceutical WST Stock Holding History

Prelude Capital Management’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,134	Closed	-$374K	–	1576
2024 Q2	$374K	Sell	1,134 -3,470	-75%	-$1.23M	0.03%	686
2024 Q1	$1.82M	Buy	4,604 +2,910	+172%	+$1.08M	0.1%	256
2023 Q4	$596K	Buy	+1,694	New	+$600K	0.04%	440
2021 Q3	–	Sell	-771	Closed	-$277K	–	2056
2021 Q2	$277K	Buy	+771	New	+$255K	0.01%	1235
2020 Q4	–	Sell	-152	Closed	-$42K	–	2069
2020 Q3	$42K	Buy	+152	New	+$40.2K	﹤0.01%	1167
2020 Q2	–	Sell	-234	Closed	-$36K	–	2293
2020 Q1	$36K	Sell	234 -273	-54%	-$42K	﹤0.01%	837
2019 Q4	$76K	Buy	507 +485	+2,205%	+$70.6K	﹤0.01%	1201
2019 Q3	$3K	Buy	+22	New	+$3.03K	﹤0.01%	1606
2019 Q1	–	Sell	-56	Closed	-$5K	–	2240
2018 Q4	$5K	Buy	+56	New	+$6.08K	﹤0.01%	1629
2014 Q3	–	Sell	-1,011	Closed	-$43K	–	2167
2014 Q2	$43K	Sell	1,011 -555	-35%	-$23.8K	0.01%	1425
2014 Q1	$69K	Buy	+1,566	New	+$73.7K	0.01%	1172
2013 Q4	–	Sell	-160	Closed	-$7K	–	1955
2013 Q3	$7K	Buy	+160	New	+$6.1K	﹤0.01%	1382

Other funds holding WST

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

APG Asset Management Amsterdam, Netherlands $40.7B AUM 39.97% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Prelude Capital Management's WST Position: Q3 2024 in Review

Prelude Capital Management sold out of West Pharmaceutical (WST) in Q3 2024, closing a stake of 1,134 shares — an estimated $374K sold.

Prelude Capital Management first reported a position in WST in Q3 2013 and held it in 12 quarters. The position peaked at $1.82M in Q1 2024. 730 funds tracked by Wall St. Rank hold WST as of Q3 2024.

Prelude Capital Management reported no remaining West Pharmaceutical position as of Q3 2024 after selling out during the quarter.
Prelude Capital Management sold 1,134 West Pharmaceutical shares in Q3 2024, an estimated $374K.
Prelude Capital Management first reported a position in West Pharmaceutical in Q3 2013 and held it in 12 quarters.
Prelude Capital Management's West Pharmaceutical position peaked at $1.82M in Q1 2024.
730 funds tracked by Wall St. Rank held West Pharmaceutical as of Q3 2024.

Based on Prelude Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.